These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 6609771)

  • 21. In vitro activity of cefamandole, cefoxitin, cefuroxime, and carbenicillin, alone and in combination with aminoglycosides against Serratia marcescens.
    Miller MA; Yousuf M; Griffin PS; Bartlett M; Crane JK
    Microbiol Immunol; 1979; 23(10):955-64. PubMed ID: 390321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative study of the "in vitro" sensitivity of cefoxitin and cephalosporins].
    Torres A; Aguirre M; Ales JM
    Rev Clin Esp; 1979 Nov; 155(4):249-52. PubMed ID: 542674
    [No Abstract]   [Full Text] [Related]  

  • 23. Cefotaxime: clinical and bacteriologic evaluation.
    Saroglou G; Paniara-Volika O; Sima A; Koltsida K; Rokas S; Kontomichalou P
    Clin Ther; 1981; 4(3):201-11. PubMed ID: 6272994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antibacterial activity of cefotaxim in comparison with seven cephalosporins].
    Braveny I; Dickert H; Machka K
    Infection; 1979; 7(5):231-6. PubMed ID: 389804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of correlation between beta-lactamase production and susceptibility to cefamandole or cefoxitin among spontaneous mutants of Enterobacteriaceae.
    Ott JL; Turner JR; Mahoney DF
    Antimicrob Agents Chemother; 1979 Jan; 15(1):14-9. PubMed ID: 311615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Microbiological evaluation of cefoxitin, a new beta-lactamase resistant cephamycin antibiotic, compared to cephalothin, cephaloridine and cefazolin].
    Schassan HH; Bentfeld G
    Fortschr Med; 1978 Aug; 96(30):1510-7. PubMed ID: 669547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of cefamandole, cefuroxime and cefoxitin on yeast fecal flora of surgical patients.
    Thomakos N; Maraki S; Liakakos T; Macheras A; Kanavaki S; Marinis E; Sehas M; Margioris AN; Samonis G
    Chemotherapy; 1998; 44(5):324-7. PubMed ID: 9732147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of cefoperazone's in vitro antibacterial activity, in comparison with other cephalosporins, on 512 gram-negative bacterial strains.
    Dainelli B; Magni A; Maragoni F; Berlutti F; Thaller MC; Filadoro F
    G Batteriol Virol Immunol; 1981; 74(1-6):8-14. PubMed ID: 6458528
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of the variations in inoculum on the cephalosporins' in vitro antibacterial activity.
    Cafarelli A; Magliulo E; Piantieri G
    G Batteriol Virol Immunol; 1981; 74(1-6):26-38. PubMed ID: 6458525
    [No Abstract]   [Full Text] [Related]  

  • 30. Beta lactamase resistance of newer cephalosporins and antimicrobial effectiveness against gram-negative bacilli.
    Farrar WE; O'Dell NM
    Infection; 1977; 5(4):224-7. PubMed ID: 413793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiation of resistance determinants to cefamandole and cefoxitin in Enterobacter cloacae strains.
    Vuye A
    Microbios; 1983; 38(153-154):159-69. PubMed ID: 6606106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cefuroxim, a new beta-lactamase stable cephalosporin].
    Simon C
    Schweiz Med Wochenschr; 1978 Sep; 108(36):1398-403. PubMed ID: 309178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inoculum effect on growth-delay time of oxacillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis exposed to cefamandole, cefazolin, and cefuroxime.
    Yourassowsky E; van der Linden MP; Crokaert F
    Antimicrob Agents Chemother; 1990 Apr; 34(4):505-9. PubMed ID: 2344158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of four recently introduced cephalosporins with respect to probability of resistance in multiresistant strains of Escherichia coli, Proteus mirabilis and Klebsiella spec. (author's transl)].
    Loch R; Schröter G
    Zentralbl Bakteriol Orig A; 1979; 245(3):312-6. PubMed ID: 44785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of beta-lactamase and the permeability barrier on the activity of cephalosporins against members of the Bacteroides fragilis group.
    Malouin F; Lamothe F
    Can J Microbiol; 1987 Mar; 33(3):262-6. PubMed ID: 3105858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies with cefuroxime and cefoxitin.
    Geddes AM; McGhie D; Ball AP; Gould I
    Scand J Infect Dis Suppl; 1978; (13):78-81. PubMed ID: 308260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The in vitro antibacterial activity of cefotaxime compared with that of cefuroxime and cefoxitin.
    King A; Warren C; Shannon K; Phillips I
    J Antimicrob Chemother; 1980 Jul; 6(4):479-94. PubMed ID: 6253433
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro bactericidal action of cephalosporins in different concentrations of serum.
    Magliulo E; Ceccarelli G; Bianchi PP; Piantieri G; Cafarelli A
    G Batteriol Virol Immunol; 1981; 74(1-6):39-47. PubMed ID: 6458527
    [No Abstract]   [Full Text] [Related]  

  • 39. The cephalosporins: activity and clinical use.
    Weinstein AJ
    Drugs; 1980 Aug; 20(2):137-54. PubMed ID: 6995096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory concentrations of cefoperazone, cefazolin, cefamandole, cephaloridine, and cefoxitin for 300 gram-negative clinical isolates.
    Trabulsi LR; Pereira da Silva Almada N; Marques LR
    Clin Ther; 1980; 3(Spec Issue):145-8. PubMed ID: 6446390
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.